Melanoma-associated antigen 3; MAGE-3
CAT No: ta-462
Synonyms/Alias:Melanoma-associated antigen 3 (111-125); MAGE-3 (111-125)
MAGE-3 (111-125) is a synthetic peptide fragment corresponding to amino acids 111 through 125 of the Melanoma Antigen Gene-3 (MAGE-3) protein, a member of the cancer-testis antigen family. As a well-characterized peptide epitope, it is widely utilized in immunological research, particularly in studies focused on antigen presentation, T cell recognition, and tumor immunology. Its defined sequence and immunogenic properties make it a valuable tool for dissecting the molecular mechanisms of immune responses to tumor-associated antigens and for evaluating peptide-based immunotherapeutic strategies in preclinical settings. MAGE-3 (111-125) is especially relevant for researchers investigating the interface between tumor biology and adaptive immunity, enabling precise experimental design in peptide-driven assays and functional studies.
Epitope mapping: MAGE-3 (111-125) serves as a critical reagent for mapping T cell epitopes, allowing researchers to identify and characterize the specific regions of the MAGE-3 protein recognized by cytotoxic T lymphocytes. By utilizing this peptide in in vitro stimulation assays, investigators can delineate the fine specificity of T cell responses, facilitating the understanding of antigenic determinants relevant to tumor recognition and immune surveillance. Such mapping efforts are essential for elucidating the molecular basis of immune targeting in cancer and for guiding the rational design of peptide-based vaccines.
Antigen presentation studies: The peptide is widely employed to assess the efficiency and specificity of antigen processing and presentation by major histocompatibility complex (MHC) molecules. By pulsing antigen-presenting cells with MAGE-3 (111-125), researchers can evaluate the capacity of various MHC alleles to present this epitope to T cells, thereby modeling critical aspects of immune recognition. These studies provide foundational insights into the dynamics of peptide-MHC interactions and contribute to the optimization of immunotherapeutic approaches targeting tumor antigens.
T cell activation assays: In immunological research, MAGE-3 (111-125) is frequently used to stimulate antigen-specific T cells in vitro, enabling the measurement of cytokine production, proliferation, and cytotoxic activity. Such assays are instrumental in profiling the functional properties of T cell populations, validating peptide immunogenicity, and screening for T cell receptor specificity. The peptide's defined sequence ensures reproducibility and precision in experimental setups designed to assess cellular immune responses.
Peptide-based vaccine development: The defined immunogenic region encompassed by MAGE-3 (111-125) makes it a valuable candidate for preclinical evaluation in peptide-based vaccine research. By incorporating this epitope into experimental vaccine formulations, researchers can investigate its capacity to elicit robust and specific immune responses against tumor antigens. These studies are fundamental for advancing the development of novel immunotherapeutic strategies and for optimizing peptide selection in vaccine design pipelines.
Assay development and validation: The peptide is also utilized as a standard or control in the development and validation of immunological assays, such as enzyme-linked immunospot (ELISPOT) and flow cytometry-based detection of antigen-specific T cells. Its well-characterized sequence and immunological relevance enable consistent benchmarking of assay performance, supporting the generation of reliable and reproducible data in experimental immunology. By serving as a reference reagent, MAGE-3 (111-125) contributes to the standardization of immune monitoring protocols in research settings.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More